ACCENDRA HEALTH INC/VA/ — Form 8-K
Filed October 9, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
On October 6, 2026, Accendra Health received notice from NYSE that its Class A Common Stock failed to meet the continued listing standard—average closing price fell below $1.00 per share over a consecutive 30 trading-day period. The company has six months to cure the deficiency and is considering alternatives including a potential reverse stock split (subject to stockholder approval by May 2027 annual meeting). Stock will remain listed during the cure period if other NYSE standards are met.
Why this rating
Material delisting risk for $677.5M company; curable within 6 months but signals underlying stock weakness and operational concerns. Reverse split risk and listing uncertainty materially threaten shareholder value.
Price action (we called it negative)
before filing · preread $0.43 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.